NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.20 -2.73 (-3.33%) GOLD FUTURES
2,329.60 +26.70 (+1.16%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,757.14 -2,022.61 (-4.23%)
NVO Jan 2025 87.500 call
| Previous close | 43.39 |
| Open | 45.15 |
| Bid | 44.75 |
| Ask | 48.10 |
| Strike | 87.50 |
| Expiry date | 2025-01-17 |
| Day's range | 44.91 - 45.15 |
| Contract range | N/A |
| Volume | |
| Open interest | 842 |
Investor's Business DailyBreakouts In Focus: Google Goes Wild As Tasty IPO Sets Up
As Google stock gaps up and gets volatile, Novo Nordisk sets up while a hot IPO and leading chipmaker break out.
GlobeNewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 1 May 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme init
BloombergThe Ozempic Effect: How a Weight Loss Wonder Drug Gobbled Up an Entire Economy
(Bloomberg) -- There is no escaping Ozempic and Wegovy. The diabetes and obesity drugs are a global phenomenon. They’ve won over the rich and famous, generated billions in sales and blown open a new market for weight loss drugs, which Goldman Sachs estimates will reach $100 billion a year by 2030.Most Read from BloombergTesla Axes Supercharger Team in Blow to Broader EV MarketNYPD Arrests Over 300 Protesters in Crackdown on College CampusesFed to Signal Delay of Interest-Rate CutsThe Ozempic Eff
